Coherus reports CMS approves Udenyca for transitional pass-through status

Coherus BioSciences announced that the Centers for Medicare and Medicaid Services, or CMS, approved Udenyca biosimilar for transitional pass-through payment status in the hospital outpatient setting. Effective April 1, Udenyca is granted 36 months of transitional pass-through status. “We launched Udenyca with a significantly lower list price, 33% below that of Neulasta. We applaud the Centers for Medicare and Medicaid Services for establishing transitional pass-through status and expanding access to therapies such as Udenyca for the nation’s Medicare patients,” said Denny Lanfear, President and CEO of Coherus.

https://thefly.com/landingPageNews.php?id=2880543